Plaintiff
4 cases as plaintiff.
Let me verify the parent company's ownership status and size.
MSP Recovery Claims, Series LLC is a Delaware series limited liability company headquartered at 2701 S. Le Jeune Road, Coral Gables, Florida, with a Miami, Florida principal office address in recent SEC filings. It is not a standalone company: per a 2025 Supreme Court corporate disclosure statement, its sole member is VRM MSP Recovery Partners, LLC, whose members include Virage Recovery Master LP and MSP Recovery, LLC; the ultimate public parent is MSP Recovery, Inc., d/b/a LifeWallet (Nasdaq: MSPR, later OTC; founded 2014 by John H. Ruiz, public since a May 2022 SPAC merger with Lionheart Acquisition Corporation II).
Products / services. MSP Recovery Claims is the claims-holding arm of a healthcare reimbursement-recovery business, not a product manufacturer. The parent describes itself as a Medicare, Medicaid, and commercial secondary-payer recovery and data-analytics company that takes irrecovable assignments of health-plan recovery rights — roughly $1.546 trillion in billed amounts — and pursues them under the Medicare Secondary Payer Act, RICO, and antitrust theories. Other offerings include the "Chase to Pay" point-of-care payer-identification tool and the LifeWallet data platform. Scale is small: ~78–88 employees; FY2024 revenue of about $18.25M against a $360.5M net loss, a $752.7M intangible impairment, and a going-concern qualification from its auditor.
Litigation posture. The tracked data show 3 cases, all as plaintiff and none as defendant — a pure serial-claimant profile, though this is claims-recovery and antitrust litigation rather than a classic patent-assertion campaign. The entity itself produces no patented products and asserts no patent portfolio of its own.
Notable cases. All three tracked matters are MSP Recovery Claims, Series LLC v. Celgene Corp. (D.N.J., filed 2021-12-10, No. 2:21-cv-20451), consolidated into In re Revlimid & Thalomid Purchaser Antitrust Litigation. The Wilcox/antitrust complaint included sham-patent-litigation and Walker Process-style allegations concerning Celgene's Revlimid and Thalomid patents — likely why it appears in a patent-litigation database — and the District of New Jersey dismissed the MSP and insurer complaints in 2024. MSP entities have filed dozens of similar suits nationwide, mostly dismissed, with Florida's Third District Court of Appeal repeatedly rejecting long-arm jurisdiction over out-of-state insurers.
Antitrust action in which the '428 patent is cited as part of the challenged Celgene patent portfolio; MSP Recovery Claims sued Celgene in D.N.J. Status is generally pending/consolidated.
Antitrust / assignment claims action referencing the '554 patent as an Orange Book-listed Revlimid patent; not asserted.
Antitrust case against Celgene listed with the REVLIMID/THALOMID matters referencing U.S. 7,977,357. No additional patents or dates were provided.
Later antitrust complaint referencing the Thalomid distribution-method patent family and mentioning the '018 patent within the family narrative. The narrative states the '018 patent was not asserted for infringement in this matter.